Product Description
Olaparib CAS#763113-22-0, this compound belongs to a class of drugs known as poly (ADP-ribose) polymerase (PARP) inhibitors. PARP enzymes play a crucial role in DNA repair mechanisms within cells. In cancer cells with specific genetic mutations, such as those in the BRCA1 and BRCA2 genes, the DNA repair pathways are often defective. Olaparib takes advantage of this weakness by inhibiting PARP enzymes, which leads to the accumulation of DNA damage in cancer cells and ultimately causes cell death.
Olaparib CAS#763113-22-0 is available in tablet form for oral administration. It is typically prescribed for patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have a mutation in the BRCA gene. It has also shown promise in the treatment of other types of cancers, including breast cancer and pancreatic cancer.
The use of Olaparib CAS#763113-22-0 has several benefits. Firstly, it offers a targeted approach to cancer treatment, specifically targeting cancer cells with defective DNA repair mechanisms while sparing normal cells. This can lead to fewer side effects compared to traditional chemotherapy. Secondly, Olaparib has demonstrated significant efficacy in prolonging progression-free survival and overall survival in patients with certain types of cancer.
In clinical trials, Olaparib CAS#763113-22-0 has shown remarkable results. Patients who received Olaparib had a longer time before their cancer progressed compared to those who received standard treatment. Additionally, the drug was well-tolerated, with common side effects including nausea, fatigue, and anemia. However, these side effects were generally manageable and did not significantly impact the quality of life of patients.
The discovery and development of Olaparib CAS#763113-22-0 represent a major breakthrough in cancer treatment. It has provided new hope for patients with difficult-to-treat cancers and has opened up new avenues for research and development in the field of targeted cancer therapies.
Olaparib Chemical Properties
|
Product Name |
Olaparib |
|
Synonyms |
1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)Methyl]-2-fluorobenzoyl]piperazin; Olaparid AZD2281; 4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; 4-[[3-[[4-(Cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]Methyl]-1(2H)-phthalazinone; KU 59436; AZD2281(olaparib)/AZD-2281; AZD2281(olaparib); 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one |
|
CAS |
763113-22-0 |
|
MF |
C24H23FN4O3 |
|
MW |
434.46 |
|
EINECS |
642-941-5 |
|
Product Categories |
APIs |
|
Density |
1.43 |
|
Solubility |
Soluble in DMSO (up to 33 mg/ml) or in Ethanol (up to 1.7 mg/ml) |
|
pka |
12.07±0.40 (Predicted) |
|
Form |
solid |
|
Color |
Off-white |
Hot Tags: Olaparib CAS#763113-22-0, China Olaparib CAS#763113-22-0 manufacturers, suppliers, Veterinary raw materials,
